REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effect - PubMed
4 hours ago
- #Clinical Trial
- #Ageing
- #Geroprotectors
- The REPROGRAM trial tests if a three-week course of geroprotectors (Metformin, Fisetin, Spermidine) can reverse ageing-related pathways in healthy adults over 70.
- Primary outcome: Reduction in senescent cells measured by SA-β-GAL in adipose tissue biopsies after intervention.
- Secondary assessments include effects on autophagy, immunosenescence, inflammation, mTOR signalling, epigenetic age, DNA damage, metabolism, stem cells, and gut microbiota.
- Randomized design with 60 participants (30 female, 30 male) assigned to one of three drug arms.
- Sample collection includes blood, adipose tissue, and stool at baseline and post-intervention for comprehensive biological analysis.
- Ethics approved (24/LO/0549); results will be published in gerontology journals and shared with participants and the public.